

January 6, 2015



# Actinium to Present at Biotech Showcase(TM) 2015

## CEO to Discuss 2014 Achievements and 2015 Corporate Milestones

NEW YORK, NY -- (Marketwired) -- 01/06/15 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will present at the Biotech Showcase Conference on January 12th, 2015 at 10:00 a.m. PT in San Francisco, CA.

The Company's presentation is scheduled to begin at 10:00 a.m. PT and will be available via a live webcast. To access the live audio webcast, please log on through a link located in the Investors section of Actinium's website at [www.actiniumpharma.com](http://www.actiniumpharma.com) under the Events tab. A replay will be available on the Actinium website within 48 hours and will be archived for a limited time.

Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Dr. Dave and other members of the management team will be available for one-on-one meetings at the conference. Members of the investment community who are interested in meeting with management should contact Evan Smith, CFA of Actinium Pharmaceuticals at (646) 840-5442 or [esmith@actiniumpharma.com](mailto:esmith@actiniumpharma.com).

### **About Actinium Pharmaceuticals**

Actinium Pharmaceuticals, Inc. ([www.actiniumpharma.com](http://www.actiniumpharma.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate lomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of lomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The

Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Contact:Actinium Pharmaceuticals, Inc.Evan Smith, CFAVP Investor Relations and Fin.

Source: Actinium Pharmaceuticals